Cargando…
A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix(®) PC1 System
SIMPLE SUMMARY: There is a great need to understand the cellular and molecular characteristics of cancer when access to the tumor is limited. Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a surrogate source of tumor material. However, the only FDA-cleared CTC...
Autores principales: | Cohen, Evan N., Jayachandran, Gitanjali, Moore, Richard G., Cristofanilli, Massimo, Lang, Julie E., Khoury, Joseph D., Press, Michael F., Kim, Kyu Kwang, Khazan, Negar, Zhang, Qiang, Zhang, Youbin, Kaur, Pushpinder, Guzman, Roberta, Miller, Michael C., Reuben, James M., Ueno, Naoto T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656921/ https://www.ncbi.nlm.nih.gov/pubmed/36358657 http://dx.doi.org/10.3390/cancers14215238 |
Ejemplares similares
-
Analytical performance of the FDA-cleared Parsortix(®) PC1 system
por: Templeman, Amy, et al.
Publicado: (2023) -
The Parsortix™ Cell Separation System—A versatile liquid biopsy platform
por: Miller, M. Craig, et al.
Publicado: (2018) -
Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling
por: Wu, Lucia Ruojia, et al.
Publicado: (2022) -
Antigen-agnostic microfluidics-based circulating tumor cell enrichment and downstream molecular characterization
por: Cohen, Evan N., et al.
Publicado: (2020) -
Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients
por: Cohen, Evan N., et al.
Publicado: (2023)